Genital herpes tests are notoriously unreliable, but better ones are in the works
Genital herpes tests are notoriously unreliable, but better ones are in the works The best blood test for herpes is only available at a single lab. What would it take for that to change? By Lauren …
Genital herpes tests are notoriously unreliable, but better ones are in the works The best blood test for herpes is only available at a single lab. W
Read Full Story at Scientific American →Why This Matters
Genital herpes affects over 490 million people worldwide, yet diagnostic blind spots persist, leaving patients in limbo about their status and treatment options. The current testing landscape mirrors the early days of HIV diagnostics, where inaccurate results fueled stigma and delayed care. Reliable testing isn’t just about accuracy—it’s about dismantling the silent burden of shame that has long shrouded sexually transmitted infections.
Background Context
The gold-standard herpes blood test, known as the HerpeSelect ELISA, has been the subject of controversy since its approval in the late 1990s, with critics pointing to false positives that can exceed 50% in low-risk populations. Meanwhile, the CDC has long cautioned against widespread screening due to these flaws, creating a paradox where the most vulnerable—those without symptoms—are left without viable testing pathways. The single lab offering the most accurate assay, Quest Diagnostics, has become a de facto gatekeeper in a market where demand far outstrips supply.
What Happens Next
With emerging PCR-based and antigen-detection tests gaining FDA traction, the next 18–24 months could see a seismic shift in how herpes is diagnosed, particularly if insurers are compelled to cover these newer, more precise options. Public health advocates are pushing for standardized guidelines that prioritize molecular testing for symptomatic cases, which would immediately reduce misdiagnosis rates. Yet the biggest hurdle remains regulatory inertia—will the FDA move fast enough to approve tests that could spare millions from unnecessary stigma?
Bigger Picture
This crisis reflects a broader failure in STI diagnostics, where outdated tools persist despite advancements in biotechnology. The push for better herpes testing aligns with growing momentum in precision medicine, where patient-specific data is finally challenging one-size-fits-all approaches to infectious disease. If successful, these innovations could set a precedent for retooling the entire STI testing infrastructure, from syphilis to HPV—where reliable diagnostics have long lagged behind scientific potential.
